ARCH Venture Partners, a leading investor in the biotech industry, is in the process of raising $3 billion for its 13th namesake fund. The Chicago-based firm filed paperwork with the SEC and expects to raise a similar amount to its previous fund in 2022. ARCH declined to comment on the new fundraising. For the full story, readers can continue to STAT+.
Source link
STAT+: ARCH Venture Partners is raising $3 billion for a life sciences fund
